Castrate-resistant prostate cancer: Therapeutic strategies

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 937-945

  Harzstark, Andrea L ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abiraterone; Angiogenesis; Bevacizumab; Castrate resistant; Chemotherapy; Endothelin; Immunotherapy; Ixabepilone; Phase III; Prostate cancer

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CALCITRIOL; DEXAMETHASONE; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE B; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; IXABEPILONE; KETOCONAZOLE; LENALIDOMIDE; MDV 3100; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; PROVENGE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SATRAPLATIN; STEROID; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLITIS; COLON CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; HEPATITIS; HUMAN; HYPOPITUITARISM; IMMUNOTHERAPY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG CANCER; METASTASIS; MONOTHERAPY; PROSTATE CANCER; REVIEW; SEIZURE; SINGLE DRUG DOSE; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77949910429     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003677382     Document Type: Review

References (44)

1. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43(3):408-410
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520
4. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669-674
5. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23(7):1439-1446
6. Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106(1):58-62
7. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-563
8. Rosenberg JE, Ryan CJ, Weinberg VK, et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009;27(17):2772-2778
9. Small E, Weinberg VK, Smith DC, et al. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: a phase II study of the DOD Prostate Cancer Clinical Trials Consortium. 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2009. Proc Am Soc Clin Oncol 2009;27(15S)
10. Beardsley F, Saad B, Eigl P, et al. A phase II study of patupilone in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel. J Clin Oncol 2009;27(15S):abstract 5139
11. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9
12. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-5438
13. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932-1936
14. Reese D, Frohlich M, Bok R, et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAB VEGF) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999;18
15. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase 2 study. Eur Urol 2008;54(5):1089-1094
16. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20(5):913-920
17. Sonpavde G, Perriman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21(2):319-324
18. Di Lorenzo G, Autorino R, De Laurentiis M, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007;6(3):313-317
19. Mathew P, Logothetis CJ, Dieringer PY, et al. Thalidomide/estramustine/ paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 2006;5(2):144-149
20. Romero S, Stanton G, DeFelice J, et al. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol 2007;25(4):284-290
21. Mathew P, Tannir N, Tu SM, et al. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 2010;65(4):811-815
22. Petrylak DP. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. Proc Am Soc Clin Oncol 2009;27(15s):abstract 5156
23. Ryan C, Efstathiou E, Smith M, et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer not exposed to ketoconazole (keto), treated with abiraterone acetate plus prednisone. J Clin Oncol 2009;27(15s):, abstract 5046
24. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-790
25. Sanda M, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151(3):622-628
26. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-3094
27. Schellhammer P, Higano C, Berger ER, et al. Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer AUA News, IMPACT study; 2009
28. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232-1237
29. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122-2132
30. DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006;4:1
31. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-1815
32. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5(7):1738-1744
33. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69(2):609-615
34. Reuben J, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106(11):2437-2444
35. Slovin S, Beer TM, Higano CS, et al. Initial phase II experience of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2009;27(152):abstract 5138
36. Kojima S, Inahara M, Suzuki H, et al. Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 2009;16(2):161-167
37. Higano C, Alumkal J, Ryan CJ, et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer J Clin Oncol 2009;27(15s):abstract 5142
38. Yin J, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003;100(19):10954-10959
39. Carducci M, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-689
40. James N, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, Phase 2 trial. Eur Urol 2009;55(5):1112-1123
41. Saad F, Hotte SJ, North SA, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol 2008;26 (20 Suppl):abstract 5002
42. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol 2010;28(7):1085-1087
43. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27(2):221-226
44. Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 2009;14(8):816-827